A carregar...
Biomarkers to predict prognosis and response to checkpoint inhibitors
Nivolumab is a fully human immunoglobulin (Ig) G4 antibody that selectively inhibits the programmed death 1 (PD-1) immune checkpoint molecule, and has recently been launched for the treatment of renal cell cancer (RCC) in Japan. Based on its promising anti-tumor efficacy and manageable safety profil...
Na minha lista:
| Publicado no: | Int J Clin Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Japan
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5533827/ https://ncbi.nlm.nih.gov/pubmed/28382562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-017-1122-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|